Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer
Journal Title
Oral Oncology
Publication Type
Online publication before print
Abstract
OBJECTIVES: The incidence of human papillomavirus positive oropharyngeal cancer (HPV+OPC) is increasing, and new biomarkers are required to better define prognostic groups and guide treatment. Infiltrating T cells have been well studied in head and neck cancer, however the presence and role of B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment has not, even though the interplay between T and B cells is increasingly being recognised. MATERIALS AND METHODS: Using CD20 immunohistochemistry (IHC) to identify B cells and TLS in a cohort of 159 HPV + OPC patients, we semi-quantitatively scored abundance and location (intra-tumoral or stromal) and correlated findings with patient survival. RESULTS: 32% (51/157) of patients had high intra-tumoral (IT) abundance of CD20(+) B cells (≥5%) and this was prognostic for improved overall survival (OS) with an adjusted hazard ratio (HR) of 0.2 (95 % CI 0.0-0.7, p = 0.014). We validated our results in an independent cohort comprising 171 HPV + OPC where 14% (23/171) were IT CD20(+) high, again showing improved survival with an adjusted HR for OS of 0.2 (95 % CI 0.0-1.4, p = 0.003). Neither stromal abundance nor the presence of TLS were prognostic in either cohort. B cells were subtyped by multispectral IHC, identifying CD20(+)CD27(+) cells, consistent with memory B cells, as the predominant subtype. Combined with validated biomarker CD103, a marker of tissue-resident memory T cells, IT CD20(+) B cells abundance was able to prognostically stratify patients further. CONCLUSIONS: CD20(+) B cell abundance has the potential to be used as a biomarker to identify good and poor prognosis HPV + OPC patients.
Keywords
B cells; Cd20; Human papillomavirus; Oropharyngeal cancer; Prognosis; Tertiary lymphoid structures
Department(s)
Laboratory Research; Pathology; Biostatistics and Clinical Trials; Medical Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-02-22 12:10:35
Last Modified: 2024-02-22 12:19:10

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙